Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant
Article
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
The aim of this study was to perform a population pharmacokinetic analysis of tacrolimus in Mexican adult kidney transplant patients to analyse the influence of clinical and genetic covariates to propose a dosage regimen. Kidney transplant patients (>18 years old) receiving oral tacrolimus treatment were included in the current study. The population pharmacokinetic model was built using a one-compartment model and the First Order Conditional Estimation method with Interaction (FOCEI via NONMEM v.7.3.). A total of 600 tacrolimus trough blood concentrations from 52 kidney transplant patients were analysed. Tacrolimus clearances were 26, 18.8 and 12.3 L/h, for patients with genetic polymorphisms CYP3A5*1*1, *1*3 and *3*3, respectively. The influence of haematocrit was inversely related to tacrolimus clearance, following an allometric power function. Total volume of distribution was 604 L. Interindividual variability associated with tacrolimus clearance and distribution volume for the final model was 33 and 63%25, respectively, with a residual error of 2.5 ng/mL. Relative bioavailability was calculated between generic formulations A (0.53) and B (1) of tacrolimus. Internal validation was performed through bootstrap analysis to evaluate the stability of the final model; external validation was performed in a new group of patients (n = 13) to estimate residual errors on basic (57.8%25) and final (34.8%25) models. Finally, stochastic simulations were performed to propose a dosage regimen based on haematocrit, CYP3A5 genotype and generic formulation of tacrolimus. A stable and predictive population pharmacokinetic model of tacrolimus was developed for Mexican adult kidney transplant patients; additionally, the proposed dosage regimen of tacrolimus should be prospectively validated. © 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
publication date
funding provided via
published in
Research
keywords
-
bioavailability; pharmacogenetics; population pharmacokinetics; renal transplantation; tacrolimus aciclovir; cytochrome P450 3A5; mycophenolate mofetil; omeprazole; prednisone; tacrolimus; verapamil; cytochrome P450 3A; immunosuppressive agent; pharmacological biomarker; tacrolimus; adult; aged; allele; Article; body mass; creatinine blood level; creatinine clearance; drug bioavailability; drug blood level; drug clearance; drug dose regimen; drug formulation; female; genetic polymorphism; genotype; hematocrit; human; immunosuppressive treatment; kidney graft; major clinical study; male; Mexican; priority journal; urea nitrogen blood level; volume of distribution; bioavailability; biological model; genetics; kidney transplantation; metabolism; Mexico; middle aged; oral drug administration; pharmacogenetics; young adult; Administration, Oral; Adult; Aged; Biological Availability; Biomarkers, Pharmacological; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Mexico; Middle Aged; Models, Biological; Pharmacogenetics; Polymorphism, Genetic; Tacrolimus; Young Adult
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue